HCA Healthcare, Inc. (HCA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: strong financial metrics but weak guidance, stable margins, and a focus on digital integration and AI. However, uncertainties around Medicaid payments and exchange reforms, alongside a lack of concrete guidance, contribute to a neutral sentiment. The Q&A highlights concerns about payer mix and volume declines, but also notes opportunities in outpatient growth and technology. Overall, the market may react cautiously, leading to a neutral stock price movement prediction.
Key Financial Performance
Revenue Revenue increased 6.7% compared to the prior year quarter. This growth was attributed to strong demand across markets, network investments, and improved capacity management.
Net Income Net income attributable to HCA Healthcare increased almost 31% year-over-year. This was driven by disciplined expense management and strong operational performance.
Diluted Earnings Per Share Diluted earnings per share as adjusted increased 29% year-over-year, reflecting strong financial performance.
Adjusted EBITDA Adjusted EBITDA increased around 11% compared to the prior year period, primarily due to strong operating performance and a $150 million increase in hurricane-impacted markets.
Admissions Admissions increased 2.4% year-over-year, driven by consistent demand growth in the 2% to 3% range.
Equivalent Admissions Equivalent admissions increased 2.5% year-over-year, in line with expectations of 2% to 3% growth.
Inpatient Surgeries Inpatient surgeries were flat year-over-year, indicating no significant change in this metric.
Outpatient Surgical Volume Outpatient surgical volume was down slightly year-over-year, though no specific reasons were provided.
ER Visits ER visits increased by 50 basis points year-over-year, reflecting a slight growth in emergency care demand.
Same Facility Net Revenue Per Equivalent Admission Same facility net revenue per equivalent admission increased 2.9% year-over-year, driven by solid revenue growth and operational improvements.
Adjusted EBITDA Margin Adjusted EBITDA margin improved by 80 basis points year-over-year, attributed to solid revenue growth, labor management, and other operating expense improvements.
Full Year Revenue Growth Full year revenue grew by 6.6% year-over-year, supported by demand growth and network investments.
Full Year Equivalent Admissions Full year equivalent admissions grew by 2.4% year-over-year, reflecting consistent demand growth.
Full Year Net Revenue Per Equivalent Admission Full year net revenue per equivalent admission increased by 4.1% year-over-year, driven by operational efficiencies and revenue growth.
Full Year Adjusted EBITDA Full year adjusted EBITDA increased by 12.1% year-over-year, with a 90 basis point improvement in adjusted EBITDA margin. This was supported by a $420 million increase in supplemental payments and $125 million from hurricane-impacted markets.
Diluted Earnings Per Share (Full Year) Diluted earnings per share as adjusted increased 28.5% year-over-year, reflecting strong financial performance.
Capital Expenditures Capital expenditures totaled $1.5 billion for the quarter and $4.9 billion for the year, reflecting significant investments in network expansion and clinical capabilities.
Share Repurchases The company purchased $2.6 billion of its outstanding shares during the quarter and $10 billion for the year, indicating a focus on returning value to shareholders.
Dividends Dividends paid were $162 million for the quarter and $679 million for the year, reflecting consistent shareholder returns.
Cash Flow from Operations Cash flow from operations was $2.4 billion for the quarter and $12.6 billion for the year, representing a 20% increase year-over-year, driven by strong operational performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Network Investments: Invested significantly in network expansion, workforce development, and clinical capabilities, resulting in approximately 47 million patient encounters in 2025.
AI and Technology: Continued investment in AI and digital innovation strategies to deliver long-term value.
Volume Growth: Achieved 19 consecutive quarters of volume growth, with admissions increasing 2.4% and equivalent admissions increasing 2.5% in Q4 2025.
Revenue Growth: Revenue increased by 6.7% in Q4 2025 compared to the prior year, with full-year revenue growth of 6.6%.
Cost Management: Advanced cost management agenda, improved balance sheet, and achieved an 80 basis point improvement in adjusted EBITDA margin in Q4 2025.
Cash Flow: Generated $12.6 billion in operating cash flow in 2025, a 20% increase over 2024.
Resiliency Program: Strengthened organizational capabilities, management systems, and leadership development to navigate policy dynamics.
Competitive Positioning: Increased hospital capacity, clinical service offerings, and outpatient facilities to enhance patient access.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Policy Environment: The company is monitoring several policy matters, including the expired enhanced premium tax credits, Medicaid supplemental payment programs, and the Rural Health Transformation program. These evolving policies could impact financial performance and operations.
Health Insurance Exchanges: An adverse impact on adjusted EBITDA between $600 million and $900 million is expected due to administrative reforms, the One Big Beautiful Bill Act, and the expiration of enhanced premium tax credits. This poses a significant financial challenge.
Supplemental Payment Programs: A decline in net benefit from supplemental payment programs is anticipated, ranging between $250 million and $450 million. This is driven by changes in programs in Tennessee, Texas, and Virginia, which could negatively affect financials.
Outpatient Surgical Volume: Outpatient surgical volume was down slightly, which could indicate challenges in maintaining or growing this revenue stream.
Medicaid Patient Costs: Medicaid supplemental payment programs do not fully cover the cost of treating Medicaid patients, creating a financial strain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenues are expected to range between $76.5 billion and $80 billion in 2026.
Adjusted EBITDA: Adjusted EBITDA is projected to range between $15.55 billion and $16.45 billion in 2026.
Net Income: Net income attributable to HCA Healthcare is expected to range between $6.5 billion and $7 billion in 2026.
Diluted Earnings Per Share: Diluted earnings per share is forecasted to range between $29.10 and $31.50 in 2026.
Capital Expenditures: Capital spending is projected to increase to a range of $5 billion to $5.5 billion in 2026, focusing on high acuity programs, new access points, and inpatient capacity.
Growth in Equivalent Admissions: Equivalent admissions are expected to grow between 2% and 3% in 2026.
Health Insurance Exchanges Impact: An adverse impact on adjusted EBITDA between $600 million and $900 million is anticipated due to administrative reforms and the expiration of enhanced premium tax credits. Resiliency initiatives are expected to offset approximately $400 million of this impact.
Supplemental Payment Programs: A decline in net benefit from supplemental payment programs is expected, ranging between $250 million and $450 million, due to changes in programs in Tennessee, Texas, and Virginia.
Margins: Full-year margins are expected to remain slightly above 20%, consistent with 2025.
Cash Flow from Operations: Cash flow from operations is projected to range between $12 billion and $13 billion in 2026.
Technology and Digital Innovation: Continued investment in technology and digital innovation strategies is planned to deliver long-term value and position the company for the future.
Share Repurchase Program: A new $10 billion share repurchase program has been authorized, with a majority expected to be completed in 2026, subject to market conditions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividend Increase: The Board declared an increase in the quarterly dividend from $0.72 to $0.78 per share.
Total Dividends Paid in 2025: $679 million in dividends were paid for the year.
Share Repurchase Program Authorization: The Board authorized a new $10 billion share repurchase program.
Share Repurchase in 2025: $2.6 billion of outstanding shares were purchased during the fourth quarter, totaling $10 billion for the year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the expense items, SWB, supplies, other operating expenses, professional fees, etc., and margin improvement opportunities in 2026?
A:The midpoint of revenue and adjusted EBITDA guidance suggests stable margins in 2026 versus 2025. Operating costs are expected to remain stable, consistent with recent years. However, physician cost pressures are anticipated to grow in the high single digits in 2026 compared to 2025.
Q:Is contract labor and general labor steady year-to-year in the guidance?
A:Yes, contract labor as a percent of SWB was 4.2% in Q4, which is expected to be the run rate for 2026. The resiliency plan is reflected in the guidance to offset exchange headwinds, showing strong cost and operating leverage.
Q:Can you provide more details on the resiliency programs and the confidence in executing them throughout the year?
A:The resiliency program focuses on revenue integrity, cost efficiencies, and capacity management. It leverages benchmarking, digital transformation with AI, and shared service platforms. The 2026 plan includes $400 million in incremental cost savings through labor efficiency, supply cost actions, and operating cost management. The program is expected to mitigate a $600-$900 million adverse impact to EBITDA from ACA subsidy expirations and administrative reforms.
Q:Are there any one-timers to adjust for 2025 when calculating core growth for 2026?
A:The guidance includes a $600-$900 million adverse impact from exchanges, a $250-$450 million decline in state supplemental payments, and a $400 million resiliency target. The company is confident in its performance and momentum heading into 2026.
Q:What is the potential impact of all CMS approvals on 2026 EBITDA?
A:The company is not sizing the potential approvals until CMS completes its review and approval processes.
Q:How much of the $400 million resiliency benefit in 2026 comes from AI initiatives, and what are the opportunities beyond 2026?
A:The $400 million is based on the implementation status of various opportunities. The resiliency program is multiyear, with ongoing efforts in AI and other areas to support cost efficiency and operational improvements beyond 2026.
Q:Can you discuss digital efforts with payers and their impact on revenue cycle, collections, or pricing?
A:The company has launched digital integration initiatives with payers, focusing on electronic data exchange, administrative simplification, and dispute resolution. These efforts have improved payer relationships, reduced payer friction, and contributed to working capital improvements, including a reduction in net days in AR.
Q:What are the updated thoughts on the rural benefit from the One Big Beautiful Bill Act and any Q1 callouts?
A:The Rural Health Transformation program is state-driven, and details are not yet finalized. The company views it as a potential opportunity but has not included it in guidance due to uncertainty. For Q1, a retro payment from Virginia in Q4 2025 was noted, which increased the full-year state supplemental payment benefit to $420 million.
Q:What are the thoughts on transitioning to a health savings account construct for enhanced subsidies?
A:It is too early to assess the impact of transitioning to health savings accounts for enhanced subsidies. The company is monitoring developments and will update as more information becomes available.
Q:How will exchange reforms and subsidy expirations impact 2026 volume and utilization?
A:The company models a 15%-20% decline in HICS volumes for 2026, with some migrating to employee-sponsored insurance and others to uninsured. Uninsured individuals are expected to have a 30% decline in utilization compared to when they had exchange coverage. The impact is included in the 2%-3% volume growth outlook.
Q:Why did outpatient surgeries decline year-over-year, and what payer categories drove the volume pressure?
A:Outpatient surgery cases declined 0.5% in Q4, with hospitals flat and ASCs down 1.5%. Medicaid was the primary driver of payer mix changes, and there was a decline in lower-intensity cases like ENT. However, outpatient revenue growth was solid, driven by other outpatient services.
Q:How did payer mix play out compared to expectations, and will Medicaid growth persist?
A:Medicaid grew 2.2% in Q4, reflecting a return to normal growth rates after the Medicaid redetermination process. Exchange growth was 2.5%, slightly down sequentially. Overall payer mix and volume growth were solid, with Medicare up 3.5% and total equivalent admissions up 2.5%.
Q:What are the M&A opportunities and capital budget priorities for 2026?
A:The company sees more opportunities in outpatient acquisitions and in-market transactions. Hospital M&A opportunities remain limited. The capital budget for 2026 is $5-$5.5 billion, with $7 billion in approved projects focused on outpatient and inpatient capacity expansion.
Q:What are the expectations for growth in specialties and procedures in 2026?
A:The company expects reasonable demand for cardiac services, emergency room services, and medical services with high acuity. Investments in outpatient facilities and networks are expected to drive growth, with outpatient revenue as a percentage of total revenue increasing.
Q:What is the impact of the recent winter storm on operations and Q1 guidance?
A:The impact of the winter storm is not yet fully assessed. The company has experience managing such events and expects to recover from any challenges.
Q:What is the status of the paused Texas Medicaid supplemental payment program?
A:The ATLIS program is under review by the new Executive Commissioner. It accounts for about one-third of the $250-$450 million decline in state supplemental payments for 2026. The company is actively engaged with state and federal partners.
Q:What are the greatest opportunities for HCA in its technology agenda, particularly with AI?
A:The technology agenda includes administrative, operational, and clinical domains. AI is being used for revenue cycle, staffing, scheduling, and clinical decision support. The company aims to improve quality, efficiency, and management effectiveness through AI and big data.
Q:What are the assumptions for bad debt and uncompensated care in 2026?
A:The guidance assumes an increase in uninsured patients due to exchange coverage loss. Patients moving from silver to bronze plans may owe more, but the impact on patient balance collections is expected to be immaterial. The company will monitor these trends in 2026.
Q:What are the expectations for 2026 margins given the headwinds and cost savings?
A:The company expects stable margins in 2026, consistent with 2025, despite headwinds from exchanges and supplemental payments. The resiliency program and operating leverage are expected to offset these challenges.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the potential impact of CMS approvals on 2026 EBITDA, stating that they are not sizing the potential approvals until CMS completes its review and approval processes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
HCA Healthcare
Healthcare share
Investor Relations
Medicaid payment
admission
agenda
area
basis point
benefit
capability
capacity
capital allocation
cash flow
demand market
development
exchange
facility
factor
improvement
income HCA
increase
investment
network
patient
payment program
policy
quarter
release
resiliency
result
system
term
today
volume
EXPD Transcript
LVMH Moët Hennessy - Louis Vuitton, Société Européenne (LV:CA) Q4 2025 Earnings Call Transcript
Unknown1-27
The earnings call presents a mixed picture. While there are strong financial metrics like high operating margins and increased cash flow, the organic growth is slightly negative, and net profit is down. The stable dividend policy is positive, but the lack of specific guidance on key brands like Dior and unclear management responses in the Q&A section create uncertainty. The stock price is likely to remain neutral as positive factors are offset by negative ones, including currency impacts and margin concerns.
HCA Healthcare, Inc. (HCA) Q4 2025 Earnings Call Transcript
Unknown1-27
The earnings call summary presents a mixed picture: strong financial metrics but weak guidance, stable margins, and a focus on digital integration and AI. However, uncertainties around Medicaid payments and exchange reforms, alongside a lack of concrete guidance, contribute to a neutral sentiment. The Q&A highlights concerns about payer mix and volume declines, but also notes opportunities in outpatient growth and technology. Overall, the market may react cautiously, leading to a neutral stock price movement prediction.
EXPD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
